首页> 美国卫生研究院文献>Proceedings of the National Academy of Sciences of the United States of America >Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
【2h】

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

机译:人类冠状病毒NL63使用严重急性呼吸综合征冠状病毒受体进入细胞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Coronavirus (CoV) infection of humans is usually not associated with severe disease. However, discovery of the severe acute respiratory syndrome (SARS) CoV revealed that highly pathogenic human CoVs (HCoVs) can evolve. The identification and characterization of new HCoVs is, therefore, an important task. Recently, a HCoV termed NL63 was discovered in patients with respiratory tract illness. Here, cell tropism and receptor usage of HCoV-NL63 were analyzed. The NL63 spike (S) protein mediated infection of different target cells compared with the closely related 229E-S protein but facilitated entry into cells known to be permissive to SARS-CoV-S-driven infection. An analysis of receptor engagement revealed that NL63-S binds angiotensin-converting enzyme (ACE) 2, the receptor for SARS-CoV, and HCoV-NL63 uses ACE2 as a receptor for infection of target cells. Potent neutralizing activity directed against NL63- but not 229E-S protein was detected in virtually all sera from patients 8 years of age or older, suggesting that HCoV-NL63 infection of humans is common and usually acquired during childhood. Here, we show that SARS-CoV shares its receptor ACE2 with HCoV-NL63. Because the two viruses differ dramatically in their ability to induce disease, analysis of HCoV-NL63 might unravel pathogenicity factors in SARS-CoV. The frequent HCoV-NL63 infection of humans suggests that highly pathogenic variants have ample opportunity to evolve, underlining the need for vaccines against HCoVs.
机译:人的冠状病毒(CoV)感染通常与严重疾病无关。但是,发现严重急性呼吸系统综合症(SARS)CoV表明,高致病性人类CoV(HCoV)可以进化。因此,鉴定和表征新的HCoV是一项重要的任务。最近,在呼吸道疾病患者中发现了一种名为NL63的HCoV。在这里,分析了细胞嗜性和HCoV-NL63受体的使用。与紧密相关的229E-S蛋白相比,NL63尖峰(S)蛋白介导了不同靶细胞的感染,但有助于进入已知允许SARS-CoV-S驱动的细胞。受体参与的分析显示,NL63-S结合了SARS-CoV的受体血管紧张素转换酶(ACE)2,而HCoV-NL63使用ACE2作为感染靶细胞的受体。实际上,在8岁以上患者的所有血清中均检测到针对NL63-的强效中和活性,但未检测到229E-S蛋白,这表明人类的HCoV-NL63感染很普遍,通常是在儿童时期获得的。在这里,我们显示SARS-CoV与HCoV-NL63共享其受体ACE2。由于两种病毒在诱导疾病的能力上有很大差异,因此对HCoV-NL63的分析可能会揭示SARS-CoV中的致病因素。人类频繁感染HCoV-NL63提示高致病性变异株有充分的进化机会,这突出表明需要针对HCoV的疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号